https://www.selleckchem.com/pr....oducts/pacritinib-sb
PURPOSE Surgery is the treatment of choice in early stage I lung adenocarcinoma. However, a considerable portion of patients experience recurrence within the first two years following complete resection. Especially suitable prognostic biomarkers are not available that identify patients at high risk for recurrence who may probably benefit from adjuvant treatment. This study aimed to identify methylation markers for early recurrence that may become important tools for the development of new treatment modalities. METHODS Genome-w
Gefällt mir
Kommentar
Teilen
